ZORYVE
Generic Name/API: lamivudine
Manufacturer: GSK
Dosage Forms & Strength & Pack Size:
Tablet, 100 mg, 28’s
Storage:
Keep this medicine out of the sight and reach of children.
Don’t take this medicine after the expiry date shown on the carton and blister.
Don’t store above 30 °C.
Do not throw away any medicines in your wastewater or household rubbish. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help to protect the environment.
INDICATIONS
ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.
ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).
The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
*The contents of this site are for reference only. We do not offer drug procurement service. All information must not be used for any commercial purpose.
